On March 1, 2018, PEAR Therapeutics announced a collaboration with Novartis to pursue marketing approval for PEAR's existing THRIVE digital therapeutic focused on schizophrenia. The THRIVE application is intended for use in conjunction with antipsychotic medications. The application provides real-time consumer monitoring and support, and real-time interventions targeting positive symptoms of schizophrenia including hallucinations and delusions. The announcement mentioned no target approval date. Novartis will provide PEAR with research funding to develop THRIVE and a new therapeutic application for people with multiple sclerosis. The terms also include an upfront payment, milestones, and royalties on net sales. Novartis . . .